Aridis Pharmaceuticals Ownership 2024 | Who Owns Aridis Pharmaceuticals Now?

Overview RevenueFinancials Chart

Institutional Ownership

0.00%

Insider Ownership

18.05%

Retail Ownership

81.95%

Institutional Holders

1.00

Aridis Pharmaceuticals Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BARTLETT & CO. WEALTH MANAGEMENT LLC	-	-	-	-150	-100.00%	-	Mar 31, 2024

Aridis Pharmaceuticals's largest institutional shareholder is BARTLETT & CO. WEALTH MANAGEMENT LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BARTLETT & CO. WEALTH MANAGEMENT LLC	-	-	-	-150	-100.00%	-	Mar 31, 2024

The largest Aridis Pharmaceuticals shareholder by % of total assets is BARTLETT & CO. WEALTH MANAGEMENT LLC. The company owns 0.00 shares of Aridis Pharmaceuticals (ARDS), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BARTLETT & CO. WEALTH MANAGEMENT LLC	-	-	-	-150	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Aridis Pharmaceuticals's largest institutional buyer is BARTLETT & CO. WEALTH MANAGEMENT LLC. The company purchased -0.15K stocks of ARDS, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BARTLETT & CO. WEALTH MANAGEMENT LLC	-	-	-	-150	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Aridis Pharmaceuticals's biggest institutional seller is BARTLETT & CO. WEALTH MANAGEMENT LLC. The company sold -0.15K shares of ARDS, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
BARTLETT & CO. WEALTH MANAGEMENT LLC	-	-	-	-150	-100.00%	-	Mar 31, 2024

Aridis Pharmaceuticals's largest sold out institutional shareholder by shares sold is BARTLETT & CO. WEALTH MANAGEMENT LLC, sold -0.15K shares, valued at -, as of undefined.

Aridis Pharmaceuticals Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
Starboard Investment Trust	0.77%	446,588	-	-	Feb 29, 2024
PERRITT FUNDS INC	0.20%	24,000	-	-	Jan 31, 2024
FIDELITY COMMONWEALTH TRUST	0.00%	5,453	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	134,779	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	251,731	-	-	Mar 31, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	365	-	-	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	2,078	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	1,851	-	-	Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	495	-	-	Mar 31, 2024

Aridis Pharmaceuticals's largest mutual fund holder by % of total assets is "Starboard Investment Trust", owning 446.59K shares, compromising 0.77% of its total assets.

Aridis Pharmaceuticals Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Dec, 23	1	-
30 Sep, 23	1	-94.44%
30 Jun, 23	18	-10.00%
31 Mar, 23	20	25.00%
31 Dec, 22	16	-
30 Sep, 22	16	-15.79%
30 Jun, 22	19	-5.00%
31 Mar, 22	20	-
31 Dec, 21	20	17.65%
30 Sep, 21	17	30.77%
30 Jun, 21	13	18.18%
31 Mar, 21	11	-
31 Dec, 20	11	57.14%
30 Sep, 20	7	16.67%
30 Jun, 20	6	-
31 Mar, 20	6	-
31 Dec, 19	6	-14.29%
30 Sep, 19	7	40.00%
30 Jun, 19	5	25.00%
31 Mar, 19	4	-
31 Dec, 18	4	-33.33%
30 Sep, 18	6	-

As of 31 Dec 23, 1 institutions are holding Aridis Pharmaceuticals's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Dec, 23	150	-98.93%
30 Sep, 23	14,077	-98.81%
30 Jun, 23	1,187,583	-66.36%
31 Mar, 23	3,530,564	6.70%
31 Dec, 22	3,308,903	143.34%
30 Sep, 22	1,359,811	4.44%
30 Jun, 22	1,302,059	-3.20%
31 Mar, 22	1,345,067	7.65%
31 Dec, 21	1,249,474	-37.26%
30 Sep, 21	1,991,440	84.89%
30 Jun, 21	1,077,071	6.29%
31 Mar, 21	1,013,352	36.71%
31 Dec, 20	741,254	305.86%
30 Sep, 20	182,636	70.57%
30 Jun, 20	107,072	12.27%
31 Mar, 20	95,368	1.94%
31 Dec, 19	93,555	-15.90%
30 Sep, 19	111,245	136.79%
30 Jun, 19	46,980	-19.53%
31 Mar, 19	58,379	299.97%
31 Dec, 18	14,596	-73.78%
30 Sep, 18	55,667	-

Aridis Pharmaceuticals (ARDS) has 150.00 shares outstanding as of 31 Dec 23, down -98.93% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Dec, 23	0.00%	26.41%
30 Sep, 23	0.04%	0.26%
30 Jun, 23	3.90%	2.90%
31 Mar, 23	11.61%	9.81%
31 Dec, 22	10.88%	18.44%
30 Sep, 22	7.68%	14.20%
30 Jun, 22	7.36%	12.74%
31 Mar, 22	7.60%	10.23%
31 Dec, 21	8.62%	3.37%
30 Sep, 21	15.99%	17.39%
30 Jun, 21	9.59%	9.77%
31 Mar, 21	9.91%	15.16%
31 Dec, 20	8.08%	192.99%
30 Sep, 20	2.05%	142.15%
30 Jun, 20	1.20%	104.96%
31 Mar, 20	1.07%	97.07%
31 Dec, 19	1.05%	64.10%
30 Sep, 19	1.28%	381.04%
30 Jun, 19	0.58%	111.72%
31 Mar, 19	0.72%	2220.54%
31 Dec, 18	0.18%	38.18%
30 Sep, 18	0.69%	-

As of 31 Dec 23, Aridis Pharmaceuticals is held by 0.00% institutional shareholders, representing a 26.41% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Dec, 23	1	-
30 Sep, 23	-	-100.00%
30 Jun, 23	7	-22.22%
31 Mar, 23	9	28.57%
31 Dec, 22	7	-
30 Sep, 22	7	-12.50%
30 Jun, 22	8	-11.11%
31 Mar, 22	9	-30.77%
31 Dec, 21	13	18.18%
30 Sep, 21	11	22.22%
30 Jun, 21	9	-
31 Mar, 21	9	12.50%
31 Dec, 20	8	100.00%
30 Sep, 20	4	-
30 Jun, 20	4	33.33%
31 Mar, 20	3	50.00%
31 Dec, 19	2	-50.00%
30 Sep, 19	4	33.33%
30 Jun, 19	3	200.00%
31 Mar, 19	1	-
31 Dec, 18	1	-83.33%
30 Sep, 18	6	-

1 institutional shareholders have increased their position in ARDS stock as of 31 Dec 23 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Dec, 23	-	-
30 Sep, 23	-	-100.00%
30 Jun, 23	2	-50.00%
31 Mar, 23	4	-
31 Dec, 22	4	-
30 Sep, 22	4	33.33%
30 Jun, 22	3	-25.00%
31 Mar, 22	4	-
31 Dec, 21	-	-100.00%
30 Sep, 21	1	-50.00%
30 Jun, 21	2	100.00%
31 Mar, 21	1	-
31 Dec, 20	1	-50.00%
30 Sep, 20	2	-
30 Jun, 20	-	-100.00%
31 Mar, 20	2	-33.33%
31 Dec, 19	3	200.00%
30 Sep, 19	1	-
30 Jun, 19	1	-50.00%
31 Mar, 19	2	-
31 Dec, 18	2	-
30 Sep, 18	-	-

- institutional shareholders have reduced their position in ARDS stock as of 31 Dec 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Dec, 23	1	-	150	-98.93%	0.00%	26.41%	1	-	-	-
30 Sep, 23	1	-94.44%	14,077	-98.81%	0.04%	0.26%	-	-100.00%	-	-100.00%
30 Jun, 23	18	-10.00%	1,187,583	-66.36%	3.90%	2.90%	7	-22.22%	2	-50.00%
31 Mar, 23	20	25.00%	3,530,564	6.70%	11.61%	9.81%	9	28.57%	4	-
31 Dec, 22	16	-	3,308,903	143.34%	10.88%	18.44%	7	-	4	-
30 Sep, 22	16	-15.79%	1,359,811	4.44%	7.68%	14.20%	7	-12.50%	4	33.33%
30 Jun, 22	19	-5.00%	1,302,059	-3.20%	7.36%	12.74%	8	-11.11%	3	-25.00%
31 Mar, 22	20	-	1,345,067	7.65%	7.60%	10.23%	9	-30.77%	4	-
31 Dec, 21	20	17.65%	1,249,474	-37.26%	8.62%	3.37%	13	18.18%	-	-100.00%
30 Sep, 21	17	30.77%	1,991,440	84.89%	15.99%	17.39%	11	22.22%	1	-50.00%
30 Jun, 21	13	18.18%	1,077,071	6.29%	9.59%	9.77%	9	-	2	100.00%
31 Mar, 21	11	-	1,013,352	36.71%	9.91%	15.16%	9	12.50%	1	-
31 Dec, 20	11	57.14%	741,254	305.86%	8.08%	192.99%	8	100.00%	1	-50.00%
30 Sep, 20	7	16.67%	182,636	70.57%	2.05%	142.15%	4	-	2	-
30 Jun, 20	6	-	107,072	12.27%	1.20%	104.96%	4	33.33%	-	-100.00%
31 Mar, 20	6	-	95,368	1.94%	1.07%	97.07%	3	50.00%	2	-33.33%
31 Dec, 19	6	-14.29%	93,555	-15.90%	1.05%	64.10%	2	-50.00%	3	200.00%
30 Sep, 19	7	40.00%	111,245	136.79%	1.28%	381.04%	4	33.33%	1	-
30 Jun, 19	5	25.00%	46,980	-19.53%	0.58%	111.72%	3	200.00%	1	-50.00%
31 Mar, 19	4	-	58,379	299.97%	0.72%	2220.54%	1	-	2	-
31 Dec, 18	4	-33.33%	14,596	-73.78%	0.18%	38.18%	1	-83.33%	2	-
30 Sep, 18	6	-	55,667	-	0.69%	-	6	-	-	-

Aridis Pharmaceuticals Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Jun 28, 2024	Patzer Eric	director	-	P-Purchase	Buy	714,286	$0.07	$50.00K	884,600
Jun 28, 2024	Truong Vu	director, officer	CEO	P-Purchase	Buy	714,286	$0.07	$50.00K	1,378,639

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Jun 28, 2024	Patzer Eric	director	-	P-Purchase	Buy	714,286	$0.07	$50.00K	884,600
Jun 28, 2024	Truong Vu	director, officer	CEO	P-Purchase	Buy	714,286	$0.07	$50.00K	1,378,639

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 15, 2023	Patzer Eric	director, officer	Executive Chairman	M-Exempt	Sell	12,000	-	-	12,000
Jun 15, 2023	HAMILTON JOHN F	director	-	M-Exempt	Sell	5,000	-	-	5,000
Jun 15, 2023	Truong Vu	director, officer	CEO and Director	M-Exempt	Sell	15,000	-	-	15,000

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 28, 2024	Windham-Bannister Susan Richards	director	-	A-Award	Buy	200,000	$0.06	$12.60K	261,000
Jun 28, 2024	HAMILTON JOHN F	director	-	A-Award	Buy	200,000	$0.06	$12.60K	269,040
Jun 28, 2024	Jafri Hasan	officer	Chief Medical Officer	A-Award	Buy	250,000	$0.06	$15.75K	382,495
Jun 28, 2024	Patzer Eric	director	-	P-Purchase	Buy	714,286	$0.07	$50.00K	884,600
Jun 28, 2024	Truong Vu	director, officer	CEO	P-Purchase	Buy	714,286	$0.07	$50.00K	1,378,639
Sep 19, 2023	HAMILTON JOHN F	director	-	A-Award	Buy	15,000	$0.08	$1.20K	91,540
Sep 19, 2023	Windham-Bannister Susan Richards	director	-	A-Award	Buy	15,000	$0.08	$1.20K	73,500
Sep 19, 2023	Patzer Eric	director, officer	Executive Chairman	A-Award	Buy	15,000	$0.08	$1.20K	161,862
Sep 19, 2023	Truong Vu	director, officer	CEO and Director	A-Award	Buy	30,000	$0.08	$2.40K	817,750
Sep 19, 2023	Jafri Hasan	officer	Chief Medical Officer	A-Award	Buy	20,000	$0.08	$1.60K	175,000
Jun 15, 2023	Patzer Eric	director, officer	Executive Chairman	M-Exempt	Buy	12,000	-	-	714,132
Jun 15, 2023	Patzer Eric	director, officer	Executive Chairman	A-Award	Buy	30,000	$0.16	$4.80K	146,862
Jun 15, 2023	Patzer Eric	director, officer	Executive Chairman	M-Exempt	Sell	12,000	-	-	12,000
Jun 15, 2023	HAMILTON JOHN F	director	-	A-Award	Buy	15,000	$0.16	$2.40K	76,540
Jun 15, 2023	HAMILTON JOHN F	director	-	M-Exempt	Buy	5,000	-	-	5,000
Jun 15, 2023	HAMILTON JOHN F	director	-	M-Exempt	Sell	5,000	-	-	5,000
Jun 15, 2023	Truong Vu	director, officer	CEO and Director	A-Award	Buy	100,000	$0.16	$16.00K	787,750
Jun 15, 2023	Truong Vu	director, officer	CEO and Director	M-Exempt	Buy	15,000	-	-	752,353
Jun 15, 2023	Truong Vu	director, officer	CEO and Director	M-Exempt	Sell	15,000	-	-	15,000
Jun 15, 2023	Windham-Bannister Susan Richards	director	-	A-Award	Buy	15,000	$0.16	$2.40K	58,500

The last insider sell of Aridis Pharmaceuticals's stock was made by Patzer Eric on Jun 15 2023, selling 12,000 shares at - per share (valued at -). The last insider buy of ARDS was made by Patzer Eric on Jun 28 2024, buying 714,286 shares at $0.07 per share (worth $50.00K).

Aridis Pharmaceuticals Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	5	-	-
Q3 2023	5	-	-
Q2 2023	12	6	200.00%
Q4 2022	8	1	800.00%
Q2 2022	2	-	-
Q4 2021	6	1	600.00%
Q3 2021	6	-	-
Q2 2021	2	-	-
Q1 2021	1	-	-
Q4 2020	-	1	-
Q2 2020	3	-	-
Q1 2020	1	1	100.00%
Q3 2019	5	-	-
Q2 2019	1	-	-
Q1 2019	2	-	-
Q4 2018	5	-	-
Q3 2018	-	17	-
Q2 2018	-	1	-
Q1 2018	-	2	-
Q4 2017	-	2	-

5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Aridis Pharmaceuticals's insiders, as of Q2 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	2	-	-
Q3 2023	-	-	-
Q2 2023	-	-	-
Q4 2022	-	-	-
Q2 2022	-	-	-
Q4 2021	-	-	-
Q3 2021	6	-	-
Q2 2021	-	-	-
Q1 2021	-	-	-
Q4 2020	-	-	-
Q2 2020	-	-	-
Q1 2020	-	-	-
Q3 2019	-	-	-
Q2 2019	-	-	-
Q1 2019	-	-	-
Q4 2018	-	-	-
Q3 2018	-	-	-
Q2 2018	-	-	-
Q1 2018	-	-	-
Q4 2017	-	-	-

As of Q2 2024, Insider owners conducted 2 open market buy trades and 0 open market sell trades of Aridis Pharmaceuticals's stocks.

Aridis Pharmaceuticals Peer Ownership

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
HOTH	Hoth Therapeutics, Inc.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
ABVC	ABVC BioPharma, Inc.
ADTX	Aditxt, Inc.
REVB	Revelation Biosciences, Inc.
RNAZ	TransCode Therapeutics, Inc.
AKTX	Akari Therapeutics, Plc
SGTX	Sigilon Therapeutics, Inc.
DRMA	Dermata Therapeutics, Inc.
VRAX	Virax Biolabs Group Limited
KOD	Kodiak Sciences Inc.
EYEN	Eyenovia, Inc.
NRBO	NeuroBo Pharmaceuticals, Inc.
UNCY	Unicycive Therapeutics, Inc.
ACST	Acasti Pharma Inc.
CGTX	Cognition Therapeutics, Inc.
ATXI	Avenue Therapeutics, Inc.

ARDS Ownership FAQ

Who Owns Aridis Pharmaceuticals?

Aridis Pharmaceuticals is owned by institutional shareholders (0.00%), insiders (18.05%), and public (81.95%). The largest institutional shareholder of Aridis Pharmaceuticals is BARTLETT & CO. WEALTH MANAGEMENT LLC (0% of total shares) and the top mutual fund owner is Starboard Investment Trust (0.77% of total shares).

Who are the major institutional shareholders of Aridis Pharmaceuticals?

Aridis Pharmaceuticals's major institutional shareholders are BARTLETT & CO. WEALTH MANAGEMENT LLC. The top five shareholders own together 0% of the company's share outstanding.

How many Aridis Pharmaceuticals shareholders are there?

As of Dec 2023, there are 1 institutional shareholders of Aridis Pharmaceuticals.

What percentage of Aridis Pharmaceuticals is owned by BARTLETT & CO. WEALTH MANAGEMENT LLC?

BARTLETT & CO. WEALTH MANAGEMENT LLC owns 0 shares of Aridis Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).